Mohammad Mehdi Ghahremanpour

Mohammad Mehdi Ghahremanpour

Auto-generated profile, based on publicly available information

Mohammad Mehdi Ghahremanpour

Yale University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in ACS Central Science
Verified
Journal Article
Open access
CZChun-Hui Zhang
Chun-Hui Zhang
ESElizabeth A. Stone
Elizabeth A. Stone
MDMaya Deshmukh
Maya Deshmukh
JIJoseph A. Ippolito
Joseph A. Ippolito
MGMohammad M. Ghahremanpour
Mohammad M. Ghahremanpour
WJWilliam L. Jorgensen
William L. Jorgensen
Starting from our previous finding of 14 known drugs as inhibitors of the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak hit perampanel to yield multiple noncovalent, nonpeptidic inhibitors with ca. 20 nM IC50 values in a kinetic assay. Free-energy perturbation (FEP) calculations for Mpro-ligand complexes provided valuable guidance on beneficial modifications that rapidly delivered the potent analogues. The design efforts were confirmed and augmented by determination of high-resolution X-ray crystal structures for five analogues bound to Mpro. Results of cell-based antiviral assays further demonstrated the potential of the compounds for treatment of COVID-19. In addition to the possible therapeutic significance, the work clearly demonstrates the power of computational chemistry for drug discovery, especially FEP-guided lead optimization.

25 October 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MGMohammad M. Ghahremanpour
Mohammad M. Ghahremanpour
JTJulian Tirado-Rives
Julian Tirado-Rives
MDMaya Deshmukh
Maya Deshmukh
JIJoseph A. Ippolito
Joseph A. Ippolito
CZChun-Hui Zhang
Chun-Hui Zhang
WJWilliam L. Jorgensen
William L. Jorgensen

21 December 2023 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
WJWilliam L. Jorgensen
William L. Jorgensen
MGMohammad M. Ghahremanpour
Mohammad M. Ghahremanpour
ASAnastasia Saar
Anastasia Saar
JTJulian Tirado-Rives
Julian Tirado-Rives

1 August 2022 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
MGMohammad M. Ghahremanpour
Mohammad M. Ghahremanpour
JTJulian Tirado-Rives
Julian Tirado-Rives
WJWilliam L. Jorgensen
William L. Jorgensen

20 January 2011 in The Journal of Chemical Physics
Verified
Journal Article
Closed access
FMFaramarz Mehrnejad
Faramarz Mehrnejad
MGMohammad Mehdi Ghahremanpour
Mohammad Mehdi Ghahremanpour
MKMahmoud Khadem-Maaref
Mahmoud Khadem-Maaref
FDFarahnoosh Doustdar
Farahnoosh Doustdar
Co-solvents such as glycerol and sorbitol are small organic molecules solvated in the cellular solutions that can have profound effects on the protein structures. Here, the molecular dynamics simulations and comparative structural analysis of magainin, as a peptide model, in pure water, 2,2,2-trifluoroethanol/water, glycerol/water, and sorbitol/water are reported. Our results show that the peptide NMR structure is largely maintained its native structure in osmolytes–water mixtures. The simulation data indicates that the stabilizing effect of glycerol and sorbitol is induced by preferential accumulation of glycerol and sorbitol molecules around the nonpolar and aromatic residues. Thus, the presence of glycerol and sorbitol molecules decreases the interactions of water molecules with the hydrophobic residues of the peptide, and the alpha helical structure is stabilized.

28 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMohammad M. Ghahremanpour
Mohammad M. Ghahremanpour
JTJulian Tirado-Rives
Julian Tirado-Rives
MDMaya Deshmukh
Maya Deshmukh
JIJoseph A. Ippolito
Joseph A. Ippolito
CZChun-Hui Zhang
Chun-Hui Zhang
WJWilliam L. Jorgensen
William L. Jorgensen
A consensus virtual screening protocol has been applied to ca. 2000 approved drugs to seek inhibitors of the main protease (M pro ) of SARS-CoV-2, the virus responsible for COVID-19. 42 drugs emerged as top candidates, and after visual analyses of the predicted structures of their complexes with M pro , 17 were chosen for evaluation in a kinetic assay for M pro inhibition. Remarkably 14 of the compounds at 100-μM concentration were found to reduce the enzymatic activity and 5 provided IC 50 values below 40 μM: manidipine (4.8 μM), boceprevir (5.4 μM), lercanidipine (16.2 μM), bedaquiline (18.7 μM), and efonidipine (38.5 μM). Structural analyses reveal a common cloverleaf pattern for the binding of the active compounds to the P1, P1’, and P2 pockets of M pro . Further study of the most active compounds in the context of COVID-19 therapy is warranted, while all of the active compounds may provide a foundation for lead optimization to deliver valuable chemotherapeutics to combat the pandemic.